SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Updated Phase 2 Survival Data of Cyclacel Pharmaceuticals, Inc.'s Sapacitabine for MDS Presented at the Eighth Annual Hematologic Malignancies 2012 Conference
Your Message